VANCOUVER and SAN DIEGO, CA, Aug. 7 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious diseases, will
deliver a presentation at the 27th Annual Canaccord Adams Global Growth
Conference in Boston. Jim DeMesa, M.D., President & CEO of MIGENIX, will
present to leading institutional investment representatives on Wednesday,
August 8, 2007 at 9:00 AM Eastern Time (6:00 AM Pacific Time) at the
InterContinental Boston Hotel.
Highlights of the presentation will include:
- An update on the Omigard(TM) Phase III international Central Line
Infection Reduction Study, or CLIRS trial, in US and European
- Phase II clinical trial results assessing the Company's oral alpha-
glucosidase inhibitor, celgosivir (MX-3253), in combination with
pegylated interferon and ribavirin to treat hepatitis C genotype 1
non-responder patients versus re-treatment with pegylated interferon
A live and archived webcast of the presentation can be accessed under the
"Events" section of the company's website, at www.migenix.com. Please connect
at least 15 minutes prior to the presentation to ensure adequate time for any
software download that may be required to join the webcast.
Dr. DeMesa will join executives from nearly 270 public and private
companies for the conference, one of the longest-running institutional events
focused exclusively on growth companies.
The Canaccord Adams Global Growth Conference is one of the oldest and
largest programs showcasing both publicly traded and privately held growth
companies. Many of the presenting public companies are covered by Canaccord
Adams' global team of equity analysts. To learn more about the conference,
please contact Nadine Miller at 617.371.3842 or
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.
James M. DeMesa, M.D.
President & CEO
For further information:
For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, email@example.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com